Immunotherapy is weaponizing the body's immune system against cancer or other disease. One of the most promising approaches is CAR-T cell therapy, yet as this technology has been implemented, it's limitations have been identified. Dr. Andy Scharenberg described the current drawbacks of CAR-T cells and how his company, Umoja, is re-engineering CAR-T cells in vivo to create more effective therapies, including approaches that can address solid tumors. Co-hosted by Donald Coon.
www.umoja-biopharma.com
Talking Biotech with Dr. Kevin Folta